Researchers at King's College London have discovered that women diagnosed with in-situ carcinoma (abnormal cells in breast ducts or lobules) face varying risks of developing full breast cancer based on their genetic makeup. In a study performed over 2,000 women with ductal carcinoma in situ (DCIS) and nearly 200 with lobular carcinoma in situ (LCIS), a genetic blood test using 313 markers assisted in predicting cancer risk. Women with DCIS who scored high on the test were twice as likely to develop cancer in the opposite breast. Meanwhile, those with LCIS had twice the risk of developing cancer in the same breast. This genetic test in combination with family history greatly enhanced the accuracy of identifying women at higher risk.
The findings imply that treatment and monitoring for women with DCIS and LCIS should not rely only on how abnormal cells appear under a microscope. Lead researchers highlight how genetic testing and family history should be part of the decision-making process. This broad approach could allow doctors to better personalize care. This could help women make more informed decisions about treatment options like surgery or hormone therapy.
This study emphasizes the growing importance of precision medicine in cancer care. By combining genetic insights with traditional pathology, doctors can provide more accurate and individualized treatment plans. This will ultimately improve outcomes and empower women to take an active role in their health decisions.
No comments:
Post a Comment